Articles

The New Mexico State Senate recently defeated a bill which would have required the public reporting of incentives paid to health care professionals for participation in marketing research studies sponsored by pharmaceutical, medical device or medical supply manufacturers.

Pharmaceutical marketing research and data analytics companies should not be required to assume responsibility for formal reporting of adverse events (AEs) uncovered during routine pharmaceutical marketing research and data analytics in the U.S. because: